Side effects of yttrium-90 radioembolization

Frontiers in Oncology

Volumn 4 JUL, Issue , 2014, Pages

  Riaz, Ahsun ^a   Awais, Rafia ^a   Salem, Riad ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN TC 99M; ANGIOTENSIN II; CONTRAST MEDIUM; IODINATED POPPYSEED OIL; IODINE 131; MICROSPHERE; PHOSPHORUS 32; RHENIUM 188; STARCH MICROSPHERE; TECHNETIUM 99M; YTTRIUM 90;

ABSCESS; ACUTE PANCREATITIS; ANGIOGRAPHY; ARTICLE; BILIARY TRACT DISEASE; BLOOD VESSEL INJURY; CANCER RADIOTHERAPY; CHILL; CHOLANGITIS; CHOLECYSTITIS; COIL EMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; DIARRHEA; DIGESTIVE SYSTEM ULCER; DOSE CALCULATION; GASTROENTERITIS; HUMAN; LIVER FIBROSIS; LYMPHOCYTOPENIA; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; RADIATION DERMATITIS; RADIATION PNEUMONIA; RADIOACTIVITY; RADIODIAGNOSIS; RADIOEMBOLIZATION; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA;

EID: 84904649769     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00198     Document Type: Article

References (70)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin (2005) 55(2):74-108. Epub 2005/03/12. PubMed PMID: 15761078.
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology (2004) 127(5 Suppl 1):S5-S16. PubMed PMID: 15508102.
3. Michel J, Suc B, Montpeyroux F, Hachemanne S, Blanc P, Domergue J, et al. Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis. J Hepatol (1997) 26(6):1274-80. PubMed PMID: 9210614.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 334(11):693-9. PubMed PMID: 8594428.
5. Lencioni R, Crocetti L. Radiofrequency ablation of liver cancer. Tech Vasc Interv Radiol (2007) 10(1):38-46. PubMed PMID: 17980317.
6. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 131(2):461-9. PubMed PMID: 16890600.
7. Lewandowski RJ, Thurston KG, Goin JE, Wong CY, Gates VL, Van Buskirk M, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135- 150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol (2005) 16(12):1641-51. PubMed PMID: 16371530.
8. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol (2001) 12(12):1711-20. PubMed PMID: 11843249.
9. Rhee TK, Lewandowski RJ, Liu DM, Mulcahy MF, Takahashi G, Hansen PD, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg (2008) 247(6):1029-35. PubMed PMID: 18520231.
10. Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol (2008) 31(3):271-9. PubMed PMID: 18525307.
11. SIR-Spheres Yttrium-90 microspheres package insert, SIRTeX Medical, Lane Cove, Australia. (2004).
12. TheraSphere Yttrium-90 microspheres package insert, MDS Nordion, Kanata, Canada. (2004).
13. Bester L, Feitelson S, Milner B, Chua TC, Morris DL. Impact of Prior Hepatectomy on the Safety and Efficacy of Radioembolization With Yttrium-90 Microspheres for Patients With Unresectable Liver Tumors. Am J Clin Oncol (2013). Epub 2013/02/08. doi: 10.1097/COC.0b013e31827deea1. PubMed PMID: 23388564.
14. van den Hoven AF, Smits ML, de Keizer B, van Leeuwen MS, van den Bosch MA, Lam MG. Identifying Aberrant Hepatic Arteries Prior to Intra-arterial Radioembolization. Cardiovasc Intervent Radiol (2014). Epub 2014/01/29. doi: 10.1007/s00270-014-0845-x. PubMed PMID: 24469409.
15. Yoon CJ, Chung JW, Cho BH, Jae HJ, Kang SG, Kim HC, et al. Hepatocellular carcinoma in the caudate lobe of the liver: angiographic analysis of tumor-feeding arteries according to subsegmental location. J Vasc Interv Radiol (2008) 19(11):1543-50; quiz 50. PubMed PMID: 18755606.
16. Liu DM, Salem R, Bui JT, Courtney A, Barakat O, Sergie Z, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol (2005) 16(7):911-35. PubMed PMID: 16002500.
17. Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, et al. Yttrium- 90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics (2005) 25 Suppl 1:S41-55. PubMed PMID: 16227496.
18. Cosin O, Bilbao JI, Alvarez S, de Luis E, Alonso A, Martinez-Cuesta A. Right gastric artery embolization prior to treatment with yttrium-90 microspheres. Cardiovasc Intervent Radiol (2007) 30(1):98-103. PubMed PMID: 17031727.
19. Salem R, Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Ibrahim S, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol (2007) 10(1):12-29. PubMed PMID: 17980315.
20. Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA, Jr., Kulik L, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol (2007) 30(4):571-92. PubMed PMID: 17516113.
21. van den Hoven AF, Smits ML, Rosenbaum CE, Verkooijen HM, van den Bosch MA, Lam MG. The Effect of Intra-Arterial Angiotensin II on the Hepatic Tumor to Non-Tumor Blood Flow Ratio for Radioembolization: A Systematic Review. PloS one (2014) 9(1):e86394. Epub 2014/01/28. doi: 10.1371/journal.pone.0086394. PubMed PMID: 24466071; PubMed Central PMCID: PMC3895031.
22. Meyer C, Pieper CC, Ezziddin S, Wilhelm KE, Schild HH, Ahmadzadehfar H. Feasibility of temporary protective embolization of normal liver tissue using degradable starch microspheres during radioembolization of liver tumours. Eur J Nucl Med Mol Imaging (2014) 41(2):231-7. Epub 2013/09/14. doi: 10.1007/s00259-013-2550-4. PubMed PMID: 24030669.
23. Hamami ME, Poeppel TD, Muller S, Heusner T, Bockisch A, Hilgard P, et al. SPECT/CT with 99mTc-MAA in Radioembolization with 90Y Microspheres in Patients with Hepatocellular Cancer. J Nucl Med (2009). PubMed PMID: 19372479.
24. Sabet A, Ahmadzadehfar H, Muckle M, Haslerud T, Wilhelm K, Biersack HJ, et al. Significance of oral administration of sodium perchlorate in planning liver directed radioembolization. J Nucl Med (2011) 52(7):1063-7. Epub 2011/06/18. doi: 10.2967/jnumed.110.083626. PubMed PMID: 21680693.
25. Lam MG, Goris ML, Iagaru AH, Mittra ES, Louie JD, Sze DY. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT. J Nucl Med (2013) 54(12):2055-61. Epub 2013/10/23. doi: 10.2967/jnumed.113.123257. PubMed PMID: 24144563.
26. Pasciak AS, Bourgeois AC, McKinney JM, Chang TT, Osborne DR, Acuff SN, et al. Radioembolization and the Dynamic Role of (90)Y PET/CT. Frontiers in oncology (2014) 4:38. Epub 2014/03/01. doi: 10.3389/fonc.2014.00038. PubMed PMID: 24579065; PubMed Central PMCID: PMC3936249.
27. Gates VL, Marshall KG, Salzig K, Williams M, Lewandowski RJ, Salem R. Outpatient single-session yttrium-90 glass microsphere radioembolization. J Vasc Interv Radiol (2014) 25(2):266-70. Epub 2013/12/18. doi: 10.1016/j.jvir.2013.11.005. PubMed PMID: 24332243.
28. Gupta A, Gill A, Shrikanthan S, Srinivas S. Nontargeted Y-90 microsphere radioembolization to duodenum visualized on Y-90 PET/CT and Bremsstrahlung SPECT/CT. Clinical nuclear medicine (2012) 37(1):98-9. Epub 2011/12/14. doi: 10.1097/RLU.0b013e318233650b. PubMed PMID: 22157042.
29. Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol (2009) 20(9):1121-30; quiz 31. Epub 2009/07/31. doi: 10.1016/j.jvir.2009.05.030. PubMed PMID: 19640737.
30. NCI. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (2009). Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 14_QuickReference_5x7.pdf.
31. Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE, Jr., Loehr SP, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys (2006) 65(2):412-25. PubMed PMID: 16690429.
32. Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, et al. Treatment of Unresectable Hepatocellular Carcinoma with Use of 90Y Microspheres (TheraSphere): Safety, Tumor Response, and Survival. J Vasc Interv Radiol (2005) 16(12):1627-39. PubMed PMID: 16371529.
33. Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol (2005) 16(7):937-45. PubMed PMID: 16002501.
34. Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol (2006) 29(4):522-9. PubMed PMID: 16729228.
35. Peterson JL, Vallow LA, Johnson DW, Heckman MG, Diehl NN, Smith AA, et al. Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients. Brachytherapy (2013) 12(6):573-9. Epub 2013/08/21. doi: 10.1016/j.brachy.2013.05.008. PubMed PMID: 23953810.
36. Young JY, Rhee TK, Atassi B, Gates VL, Kulik L, Mulcahy MF, et al. Radiation Dose Limits and Liver Toxicities Resulting from Multiple Yttrium-90 Radioembolization Treatments for Hepatocellular Carcinoma. J Vasc Interv Radiol (2007) 18(11):1375-82. PubMed PMID: 18003987.
37. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer (2008) 112(7):1538-46. PubMed PMID: 18260156.
38. Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, et al. Treatment Parameters and Outcome in 680 Treatments of Internal Radiation with Resin Yttrium-90 Microspheres for Unresectable Hepatic Tumors. Int J Radiation Oncology Biol Phys (2009 In Press).
39. Lam MG, Louie JD, Iagaru AH, Goris ML, Sze DY. Safety of repeated yttrium- 90 radioembolization. Cardiovasc Intervent Radiol (2013) 36(5):1320-8. Epub 2013/01/29. doi: 10.1007/s00270-013-0547-9. PubMed PMID: 23354961.
40. Lam MG, Abdelmaksoud MH, Chang DT, Eclov NC, Chung MP, Koong AC, et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int J Radiat Oncol Biol Phys (2013) 87(2):323-9. Epub 2013/07/16. doi: 10.1016/j.ijrobp.2013.05.041. PubMed PMID: 23849697.
41. Hamoui N, Ryu RK. Hepatic radioembolization complicated by fulminant hepatic failure. Seminars in interventional radiology (2011) 28(2):246-51. Epub 2012/06/02. doi: 10.1055/s-0031-1280674. PubMed PMID: 22654272; PubMed Central PMCID: PMC3193342.
42. Piana PM, Gonsalves CF, Sato T, Anne PR, McCann JW, Bar Ad V, et al. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. J Vasc Interv Radiol (2011) 22(10):1373-9. Epub 2011/07/19. doi: 10.1016/j.jvir.2011.06.006. PubMed PMID: 21764600.
43. Ayav A, Habib N, Jiao LR. Portal hypertension secondary to 90Yttrium microspheres: an unknown complication. J Clin Oncol (2005) 23(32):8275-6. PubMed PMID: 16278485.
44. Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai V, et al. Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intraarterial Radiotherapy with (90)Yttrium Microspheres. Dig Dis Sci (2008) 53(9):2556-63. PubMed PMID: 18231857.
45. Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol (2013) 58(1):73-80. Epub 2012/09/25. doi: 10.1016/j.jhep.2012.09.003. PubMed PMID: 23000237; PubMed Central PMCID: PMC3527660.
46. Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol (2008) 19(5):691-7. Epub 2008/04/29. doi: 10.1016/j.jvir.2008.01.003. PubMed PMID: 18440457.
47. Rhee TK, Naik NK, Deng J, Atassi B, Mulcahy MF, Kulik LM, et al. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol (2008) 19(8):1180-6. PubMed PMID: 18656011.
48. Ibrahim SM, Nikolaidis P, Miller FH, Lewandowski RJ, Ryu RK, Sato KT, et al. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging (2008). PubMed PMID: 18777189.
49. Ng SS, Yu SC, Lai PB, Lau WY. Biliary Complications Associated with Selective Internal Radiation (SIR) Therapy for Unresectable Liver Malignancies. Dig Dis Sci (2008) 53(10):2813-7. PubMed PMID: 18320307.
50. Salem R, Thurston KG. Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies: Part 2: Special Topics. J Vasc Interv Radiol (2006) 17(9):1425-39. PubMed PMID: 16990462.
51. Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol (2008) 31(5):431-8. PubMed PMID: 18838878.
52. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys (1995) 33(4):919-24. PubMed PMID: 7591903.
53. Yu N, Srinivas SM, Difilippo FP, Shrikanthan S, Levitin A, McLennan G, et al. Lung dose calculation with SPECT/CT for (9)(0)Yittrium radioembolization of liver cancer. Int J Radiat Oncol Biol Phys (2013) 85(3):834-9. Epub 2012/08/09. doi: 10.1016/j.ijrobp.2012.06.051. PubMed PMID: 22871239.
54. Wright CL, Werner JD, Tran JM, Gates VL, Rikabi AA, Shah MH, et al. Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. J Vasc Interv Radiol (2012) 23(5):669-74. Epub 2012/04/25. doi: 10.1016/j.jvir.2012.01.059. PubMed PMID: 22525023.
55. Carretero C, Munoz-Navas M, Betes M, Angos R, Subtil JC, Fernandez-Urien I, et al. Gastroduodenal Injury After Radioembolization of Hepatic Tumors. Am J Gastroenterol (2007). PubMed PMID: 17355414.
56. Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, et al. Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol (2007) 18(4):553-61; quiz 62. PubMed PMID: 17446547.
57. Szyszko T, Al-Nahhas A, Tait P, Rubello D, Canelo R, Habib N, et al. Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres. Nucl Med Commun (2007) 28(1):21-4. PubMed PMID: 17159545.
58. Mallach S, Ramp U, Erhardt A, Schmitt M, Haussinger D. An uncommon cause of gastro-duodenal ulceration. World J Gastroenterol (2008) 14(16):2593- 5. PubMed PMID: 18442213.
59. Veloso N, Brandao C, Goncalves B, Costa L, Coimbra N, Jacome M, et al. Gastroduodenal ulceration following liver radioembolization with yttrium-90. Endoscopy (2013) 45 Suppl 2 UCTN:E108-9. Epub 2013/04/03. doi: 10.1055/s- 0032-1326346. PubMed PMID: 23526501.
60. Lam MG, Banerjee S, Louie JD, Abdelmaksoud MH, Iagaru AH, Ennen RE, et al. Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization. Cardiovasc Intervent Radiol (2013) 36(6):1536-47. Epub 2013/02/26. doi: 10.1007/s00270-013-0579-1. PubMed PMID: 23435742.
61. Hoffmann RT, Jakobs TF, Kubisch CH, Stemmler HJ, Trumm C, Tatsch K, et al. Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease-Is it feasible? European journal of radiology (2010) 74(1):199-205. Epub 2009/03/10. doi: 10.1016/j.ejrad.2009.02.001. PubMed PMID: 19269763.
62. Wang DS, Louie JD, Kothary N, Shah RP, Sze DY. Prophylactic topically applied ice to prevent cutaneous complications of nontarget chemoembolization and radioembolization. J Vasc Interv Radiol (2013) 24(4):596-600. Epub 2013/03/26. doi: 10.1016/j.jvir.2012.12.020. PubMed PMID: 23522163.
63. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl (2004) 10(2 Suppl 1):S107-10. PubMed PMID: 14762849.
64. Lam MG, Banerjee A, Louie JD, Sze DY. Splenomegaly-Associated Thrombocytopenia After Hepatic Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol (2013). Epub 2013/10/05. doi: 10.1007/s00270-013-0742-8. PubMed PMID: 24091754.
65. Wiggins E, Ibrahim SM, Lewandowski RJ, Sato KT, Omary RA, Salem R. Abstract No. 124: Effect of Chemotherapy on Hepatic Vasculature in Patients Undergoing Y-90 Radioembolization for Metastatic Disease. Journal of vascular and interventional radiology : JVIR (2008) 19(2):S48-S9. PubMed PMID: S1051- 0443(07)01660-0.
66. Murthy R, Eng C, Krishnan S, Madoff DC, Habbu A, Canet S, et al. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol (2007) 18(12):1588-91. PubMed PMID: 18057297.
67. Lilly MP, Reichman W, Sarazen AA, Jr., Carney WI, Jr. Anatomic and clinical factors associated with complications of transfemoral arteriography. Ann Vasc Surg (1990) 4(3):264-9. PubMed PMID: 2340248.
68. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 141(2 Suppl):e326S-50S. Epub 2012/02/15. doi: 10.1378/chest.11-2298. PubMed PMID: 22315266; PubMed Central PMCID: PMC3278059.
69. Salem R, Thurston KG. Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies: Part 1: Technical and Methodologic Considerations. J Vasc Interv Radiol (2006) 17(8):1251-78. PubMed PMID: 16923973.
70. South CD, Meyer MM, Meis G, Kim EY, Thomas FB, Rikabi AA, et al. Yttrium- 90 microsphere induced gastrointestinal tract ulceration. World J Surg Oncol (2008) 6:93. PubMed PMID: 18764938.